Publication list - Publika - Scientific publications from Oslo University Hospital

Publications by Gustav Gaudernack

233 publications found

Original articles

Mensali N, Köksal H, Joaquina S, Wernhoff P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L, Juzeniene A, Myhre MR, Fåne A, Ramírez CC, Maggadottir SM, Duru AD, Georgoudaki AM, Grad I, Maturana AD, Gaudernack G, Kvalheim G, Carcaboso AM, de Alava E, Donnadieu E, Bruland ØS, Menendez P et al. (2023)
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
Nat Commun, 14 (1), 3375
DOI 10.1038/s41467-023-39097-x, PubMed 37291203

Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G (2022)
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
J Transl Med, 20 (1), 419
DOI 10.1186/s12967-022-03624-z, PubMed 36089578

Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
J Immunother Cancer, 10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827

Anzar I, Sverchkova A, Samarakoon P, Ellingsen EB, Gaudernack G, Stratford R, Clancy T (2022)
Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants
HLA, 99 (4), 313-327
DOI 10.1111/tan.14562, PubMed 35073457

Mensali N, Dillard P, Fayzullin A, Köksal H, Gaudernack G, Kvalheim G, Inderberg EM, Wälchli S (2021)
"Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms
FASEB J, 35 (9), e21750
DOI 10.1096/fj.202100025R, PubMed 34424568

Dillard P, Casey N, Pollmann S, Vernhoff P, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2021)
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
Oncoimmunology, 10 (1), 1936757
DOI 10.1080/2162402X.2021.1936757, PubMed 34235003

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther, 29 (3), 1199-1213
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301

Nasi A, McArdle S, Gaudernack G, Westman G, Melief C, Rockberg J, Arens R, Kouretas D, Sjölin J, Mangsbo S (2020)
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention
Toxicol Rep, 7, 768-771
DOI 10.1016/j.toxrep.2020.06.003, PubMed 32632359

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2019)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732

Kyte JA, Fåne A, Pule M, Gaudernack G (2019)
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
Oncoimmunology, 8 (4), e1565236
DOI 10.1080/2162402X.2019.1565236, PubMed 30906659

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853

Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S (2019)
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Oncoimmunology, 8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591

Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S (2017)
A TCR-based Chimeric Antigen Receptor
Sci Rep, 7 (1), 10713
DOI 10.1038/s41598-017-11126-y, PubMed 28878363

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Cancer Immunol Immunother, 66 (7), 891-901
DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
Oncoimmunology, 6 (4), e1302631
DOI 10.1080/2162402X.2017.1302631, PubMed 28507809

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886

Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747

Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, Stiller M, Becker JC, Lennerz V, Wölfel T, Schadendorf D, Griewank K, Paschen A (2016)
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency
Cancer Res, 76 (15), 4347-58
DOI 10.1158/0008-5472.CAN-16-0008, PubMed 27261508

Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA (2015)
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
Cancer Immunol Immunother, 64 (12), 1609-21
DOI 10.1007/s00262-015-1766-5, PubMed 26498005

Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther, 22 (5), 391-403
DOI 10.1038/gt.2015.4, PubMed 25652098

Mellstedt H, Gaudernack G, Gerritsen WR, Huber C, Melero I, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C (2014)
Awareness and understanding of cancer immunotherapy in Europe
Hum Vaccin Immunother, 10 (7), 1828-35
DOI 10.4161/hv.28943, PubMed 25424789

del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R, González-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2013)
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Int J Cancer, 134 (1), 102-13
DOI 10.1002/ijc.28338, PubMed 23784959

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Cancer Immunol Immunother, 62 (9), 1499-509
DOI 10.1007/s00262-013-1453-3, PubMed 23817721

Wang P, Suo Z, Wang M, Høifødt HK, Fodstad O, Gaudernack G, Kvalheim G (2013)
In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines
Exp Hematol Oncol, 2 (1), 16
DOI 10.1186/2162-3619-2-16, PubMed 23738757

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2013)
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
Leuk Lymphoma, 54 (10), 2205-14
DOI 10.3109/10428194.2013.774392, PubMed 23391141

Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, Wang M, Westerdaal NA, Kvalheim G, Gaudernack G (2013)
Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines
PLoS One, 8 (3), e57020 (Retracted)
DOI 10.1371/journal.pone.0057020, PubMed 23469181

Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012)
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
Oncoimmunology, 1 (5), 670-686
DOI 10.4161/onci.20426, PubMed 22934259

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
Leuk Lymphoma, 53 (10), 1934-44
DOI 10.3109/10428194.2012.682307, PubMed 22475179

Torfoss D, Sandstad B, Mollnes TE, Høiby EA, Holte H, Bjerner J, Bjøro T, Gaudernack G, Kvalheim G, Kvaløy S (2011)
The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily
Scand J Immunol, 74 (6), 632-9
DOI 10.1111/j.1365-3083.2011.02618.x, PubMed 21883353

Adamczak M, Hoel HJ, Gaudernack G, Barbasz J, Szczepanowicz K, Warszyński P (2011)
Polyelectrolyte multilayer capsules with quantum dots for biomedical applications
Colloids Surf B Biointerfaces, 90, 211-6
DOI 10.1016/j.colsurfb.2011.10.028, PubMed 22078925

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169

Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G (2011)
Vaccination of patients with cutaneous melanoma with telomerase-specific peptides
Cancer Immunol Immunother, 60 (11), 1553-64
DOI 10.1007/s00262-011-1061-z, PubMed 21681371

Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
Clin Cancer Res, 17 (13), 4568-80
DOI 10.1158/1078-0432.CCR-11-0184, PubMed 21586625

Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011)
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Cancer Immunol Immunother, 60 (6), 809-18
DOI 10.1007/s00262-011-0991-9, PubMed 21365467

Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, Gaudernack G, Buanes T (2011)
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
Int J Cancer, 128 (5), 1120-8
DOI 10.1002/ijc.25449, PubMed 20473937

Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM (2010)
Transiently redirected T cells for adoptive transfer
Cytotherapy, 13 (5), 629-40
DOI 10.3109/14653249.2010.542461, PubMed 21174490

Abrahamsen IW, Stronen E, Wälchli S, Johansen JN, Kjellevoll S, Kumari S, Komada M, Gaudernack G, Tjonnfjord G, Toebes M, Schumacher TN, Lund-Johansen F, Olweus J (2010)
Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif
Leukemia, 24 (11), 1901-9
DOI 10.1038/leu.2010.186, PubMed 20844564

Szczepanowicz K, Hoel HJ, Szyk-Warszynska L, Bielańska E, Bouzga AM, Gaudernack G, Simon C, Warszynski P (2010)
Formation of biocompatible nanocapsules with emulsion core and pegylated shell by polyelectrolyte multilayer adsorption
Langmuir, 26 (15), 12592-7
DOI 10.1021/la102061s, PubMed 20604580

Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, Kvalheim G, Aarvak T (2010)
Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy
J Immunol Methods, 355 (1-2), 52-60
DOI 10.1016/j.jim.2010.02.004, PubMed 20171968

Stronen E, Abrahamsen IW, Gaudernack G, Wälchli S, Munthe E, Buus S, Johansen FE, Lund-Johansen F, Olweus J (2009)
Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells
Scand J Immunol, 69 (4), 319-28
DOI 10.1111/j.1365-3083.2008.02223.x, PubMed 19284496

Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G (2009)
Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination
Cancer Immunol Immunother, 58 (10), 1609-26
DOI 10.1007/s00262-009-0670-2, PubMed 19221745

Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Håkansson L (2009)
Improving the efficacy of cancer immunotherapy
Eur J Cancer, 45 (8), 1424-31
DOI 10.1016/j.ejca.2008.12.017, PubMed 19167214

Gao Q, Geng L, Kvalheim G, Gaudernack G, Suo Z (2009)
Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3
Ultrastruct Pathol, 33 (4), 175-81
DOI 10.1080/01913120903086072, PubMed 19728235

Kloster MM, Hafte TT, Moltzau LR, Naderi EH, Dahle MK, Skålhegg BS, Gaudernack G, Levy FO, Naderi S, Blomhoff HK (2008)
EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase
Cell Signal, 20 (6), 1169-78
DOI 10.1016/j.cellsig.2008.02.007, PubMed 18406106

Alsøe L, Stacy JE, Fosså A, Funderud S, Brekke OH, Gaudernack G (2007)
Identification of prostate cancer antigens by automated high-throughput filter immunoscreening
J Immunol Methods, 330 (1-2), 12-23
DOI 10.1016/j.jim.2007.10.011, PubMed 18045611

Jarnjak-Jankovic S, Hammerstad H, Saebøe-Larssen S, Kvalheim G, Gaudernack G (2007)
A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines
BMC Cancer, 7, 119
DOI 10.1186/1471-2407-7-119, PubMed 17608923

Jarnjak-Jankovic S, Saebøe-Larssen S, Kvalheim G, Gaudernack G (2007)
mRNA transfection of DC in the immature or mature state: comparable in vitro priming of Th and cytotoxic T lymphocytes against DC electroporated with tumor cell line-derived mRNA
Cytotherapy, 9 (6), 587-92
DOI 10.1080/14653240701466354, PubMed 17882723

Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes T, Gaudernack G (2006)
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study
Br J Cancer, 95 (11), 1474-82
DOI 10.1038/sj.bjc.6603437, PubMed 17060934

Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2006)
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Cancer Immunol Immunother, 56 (5), 659-75
DOI 10.1007/s00262-006-0222-y, PubMed 16947019

Saebøe-Larssen S, Fossberg E, Gaudernack G (2006)
Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues
BMC Mol Biol, 7, 26
DOI 10.1186/1471-2199-7-26, PubMed 16939641

Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Cancer Gene Ther, 13 (10), 905-18
DOI 10.1038/sj.cgt.7700961, PubMed 16710345

Kyte JA, Gaudernack G (2006)
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
Cancer Immunol Immunother, 55 (11), 1432-42
DOI 10.1007/s00262-006-0161-7, PubMed 16612595

Gaudernack G (2006)
Prospects for vaccine therapy for pancreatic cancer
Best Pract Res Clin Gastroenterol, 20 (2), 299-314
DOI 10.1016/j.bpg.2006.01.003, PubMed 16549329

Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, Gaudernack G (2006)
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Cancer Immunol Immunother, 55 (12), 1553-64
DOI 10.1007/s00262-006-0145-7, PubMed 16491401

Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G (2005)
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
Br J Cancer, 93 (7), 749-56
DOI 10.1038/sj.bjc.6602761, PubMed 16136047

Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, Wesenberg F, Olafsen MR, Gaudernack G (2005)
Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma
Cancer Gene Ther, 12 (8), 699-707
DOI 10.1038/sj.cgt.7700820, PubMed 15846368

Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G (2005)
Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
Cancer Gene Ther, 12 (6), 579-91
DOI 10.1038/sj.cgt.7700837, PubMed 15818380

Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, Wesenberg F, Gaudernack G (2005)
Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia
BMC Cancer, 5, 20
DOI 10.1186/1471-2407-5-20, PubMed 15720715

Kersten C, Delabie J, Gaudernack G, Smeland EB, Fosså A (2004)
Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2
Cancer Immunol Immunother, 53 (12), 1119-26
DOI 10.1007/s00262-004-0558-0, PubMed 15185015

Fosså A, Berner A, Fosså SD, Hernes E, Gaudernack G, Smeland EB (2004)
NY-ESO-1 protein expression and humoral immune responses in prostate cancer
Prostate, 59 (4), 440-7
DOI 10.1002/pros.20025, PubMed 15065093

Breivik J, Gaudernack G (2004)
Resolving the evolutionary paradox of genetic instability: a cost-benefit analysis of DNA repair in changing environments
FEBS Lett, 563 (1-3), 7-12
DOI 10.1016/S0014-5793(04)00282-0, PubMed 15063714

Fosså A, Alsøe L, Crameri R, Funderud S, Gaudernack G, Smeland EB (2004)
Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display
Cancer Immunol Immunother, 53 (5), 431-8
DOI 10.1007/s00262-003-0458-8, PubMed 14747957

Lazarova P, Lijun M, Hammerstad H, Nesland J, Gaudernack G, Kvalheim G (2004)
Experimental attempt to introduce a vaccine therapy by using DC-developed from CD34+cells
NATO SCI SER I LIFE, 361, 134

Mu LJ, Lazarova P, Gaudernack G, Saeboe-Larssen S, Kvalheim G (2004)
Development of a clinical grade procedure for generation of mRNA transfected dendritic cells from purified frozen CD34(+) blood progenitor cells
Int J Immunopathol Pharmacol, 17 (3), 255-63
DOI 10.1177/039463200401700305, PubMed 15461859

Mu LJ, Gaudernack G, Saebøe-Larssen S, Hammerstad H, Tierens A, Kvalheim G (2003)
A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines
Scand J Immunol, 58 (5), 578-86
DOI 10.1046/j.1365-3083.2003.01333.x, PubMed 14629630

Bjorheim J, Minarik M, Gaudernack G, Ekstrom PO (2003)
Evaluation of denaturing conditions in analysis of DNA variants applied to multi-capillary electrophoresis instruments
J. Sep. Sci., 26 (12-13), 1163-1168
DOI 10.1002/jssc.200301521

Bjørheim J, Abrahamsen TW, Kristensen AT, Gaudernack G, Ekstrøm PO (2003)
Approach to analysis of single nucleotide polymorphisms by automated constant denaturant capillary electrophoresis
Mutat Res, 526 (1-2), 75-83
DOI 10.1016/s0027-5107(03)00033-2, PubMed 12714185

Bjørheim J, Gaudernack G, Giercksky KE, Ekstrøm PO (2003)
Direct identification of all oncogenic mutants in KRAS exon 1 by cycling temperature capillary electrophoresis
Electrophoresis, 24 (1-2), 63-9
DOI 10.1002/elps.200390032, PubMed 12652573

Ekstrøm PO, Bjørheim J, Gaudernack G, Giercksky KE (2002)
Population screening of single-nucleotide polymorphisms exemplified by analysis of 8000 alleles
J Biomol Screen, 7 (6), 501-6
DOI 10.1177/1087057102238623, PubMed 14599347

Gjertsen MK, Saeterdal I, Saebøe-Larssen S, Gaudernack G (2002)
HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes
J Mol Med (Berl), 81 (1), 43-50
DOI 10.1007/s00109-002-0390-y, PubMed 12545248

Bjorheim J, Gaudernack G, Ekstrom PO (2002)
Melting gel techniques in single nucleotide polymorphism and mutation detection: From theory to automation
J. Sep. Sci., 25 (10-11), 637-647
DOI 10.1002/1615-9314(20020701)25:10/11<637::AID-JSSC637>3.0.CO;2-L

Bjørheim J, Minarik M, Gaudernack G, Ekstrøm PO (2002)
Mutation detection in KRAS Exon 1 by constant denaturant capillary electrophoresis in 96 parallel capillaries
Anal Biochem, 304 (2), 200-5
DOI 10.1006/abio.2002.5629, PubMed 12009696

Fosså A, Lilleby W, Fosså SD, Gaudernack G, Torlakovic G, Berner A (2002)
Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy
Int J Cancer, 99 (1), 100-5
DOI 10.1002/ijc.10286, PubMed 11948499

Saebøe-Larssen S, Fossberg E, Gaudernack G (2002)
mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT)
J Immunol Methods, 259 (1-2), 191-203
DOI 10.1016/s0022-1759(01)00506-3, PubMed 11730854

Paulsen JE, Bjørheim J, Røe J, Eide TJ, Alexander J, Gaudernack G (2002)
Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane
Anticancer Res, 22 (1A), 171-5
PubMed 12017282

Saeterdal I, Gjertsen MK, Straten P, Eriksen JA, Gaudernack G (2001)
A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells
Cancer Immunol Immunother, 50 (9), 469-76
DOI 10.1007/s002620100222, PubMed 11761441

Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G (2001)
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer
Proc Natl Acad Sci U S A, 98 (23), 13255-60
DOI 10.1073/pnas.231326898, PubMed 11687624

Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT et al. (2001)
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
Br J Cancer, 85 (5), 692-6
DOI 10.1054/bjoc.2001.1964, PubMed 11531254

Hunger RE, Brand CU, Streit M, Eriksen JA, Gjertsen MK, Saeterdal I, Braathen LR, Gaudernack G (2001)
Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant
Exp Dermatol, 10 (3), 161-7
DOI 10.1034/j.1600-0625.2001.010003161.x, PubMed 11380611

Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Søreide O, Eriksen JA, Møller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G (2001)
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma
Int J Cancer, 92 (3), 441-50
DOI 10.1002/ijc.1205, PubMed 11291084

Bjørheim J, Ekstrøm PO, Fossberg E, Børresen-Dale AL, Gaudernack G (2001)
Automated constant denaturant capillary electrophoresis applied for detection of KRAS exon 1 mutations
Biotechniques, 30 (5), 972-5
DOI 10.2144/01305st01, PubMed 11355359

Bjørheim J, Gaudernack G, Ekstrøm PO (2001)
Mutation analysis of TP53 exons 5-8 by automated constant denaturant capillary electrophoresis
Tumour Biol, 22 (5), 323-7
DOI 10.1159/000050634, PubMed 11553863

Fosså A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, Fosså SD, Paus E, Smeland EB, Gaudernack G (2000)
Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer
Br J Cancer, 83 (6), 743-9
DOI 10.1054/bjoc.2000.1365, PubMed 10952778

Breivik J, Gaudernack G (1999)
Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis
Semin Cancer Biol, 9 (4), 245-54
DOI 10.1006/scbi.1999.0123, PubMed 10448112

Gaudernack G, Gjertsen MK (1999)
Combination of GM-CSF with antitumour vaccine strategies
Eur J Cancer, 35 Suppl 3, S33-5
DOI 10.1016/s0959-8049(99)00088-x, PubMed 10645220

Berg K, Selbo PK, Prasmickaite L, Tjelle TE, Sandvig K, Moan J, Gaudernack G, Fodstad O, Kjølsrud S, Anholt H, Rodal GH, Rodal SK, Høgset A (1999)
Photochemical internalization: a novel technology for delivery of macromolecules into cytosol
Cancer Res, 59 (6), 1180-3
PubMed 10096543

Baekkevold ES, Jahnsen FL, Johansen FE, Bakke O, Gaudernack G, Brandtzaeg P, Haraldsen G (1999)
Culture characterization of differentiated high endothelial venule cells from human tonsils
Lab Invest, 79 (3), 327-36
PubMed 10092069

Bjørheim J, Lystad S, Lindblom A, Kressner U, Westring S, Wahlberg S, Lindmark G, Gaudernack G, Ekstrøm P, Røe J, Thilly WG, Børresen-Dale AL (1998)
Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction
Mutat Res, 403 (1-2), 103-12
DOI 10.1016/s0027-5107(98)00057-8, PubMed 9726011

Pettersen RD, Gaudernack G, Olafsen MK, Lie SO, Hestdal K (1998)
The TCR-binding region of the HLA class I alpha2 domain signals rapid Fas-independent cell death: a direct pathway for T cell-mediated killing of target cells?
J Immunol, 160 (9), 4343-52
PubMed 9574538

Saeterdal I, thor Straten P, Myklebust JH, Kirkin AF, Gjertsen MK, Gaudernack G (1998)
Generation and characterization of gp100 peptide-specific NK-T cell clones
Int J Cancer, 75 (5), 794-803
DOI 10.1002/(sici)1097-0215(19980302)75:5<794::aid-ijc21>3.0.co;2-5, PubMed 9495251

Gjertsen MK, Bakka A, Buanes T, Rosseland A, Quist HL, Faerden A, Eriksen JA, Moller M, Baksaas I, Soreide O, Giercksky KE, Gaudernack G (1998)
Intradermal ras peptide vaccines with GM-CSF as adjuvant
17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 149-152

Gjertsen MK, Gaudernack G (1998)
Mutated Ras peptides as vaccines in immunotherapy of cancer
Vox Sang, 74 Suppl 2, 489-95
DOI 10.1111/j.1423-0410.1998.tb05462.x, PubMed 9704487

Breivik J, Lothe RA, Meling GI, Rognum TO, Børresen-Dale AL, Gaudernack G (1997)
Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors
Int J Cancer, 74 (6), 664-9
DOI 10.1002/(sici)1097-0215(19971219)74:6<664::aid-ijc18>3.0.co;2-5, PubMed 9421366

Rasmussen AM, Horejsí V, Levy FO, Blomhoff HK, Smeland EB, Beiske K, Michaelsen TE, Gaudernack G, Funderud S (1997)
CDw78--a determinant on a major histocompatibility complex class II subpopulation that can be induced to associate with the cytoskeleton
Eur J Immunol, 27 (12), 3206-13
DOI 10.1002/eji.1830271218, PubMed 9464807

Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G (1997)
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation
Int J Cancer, 72 (5), 784-90
DOI 10.1002/(sici)1097-0215(19970904)72:5<784::aid-ijc14>3.0.co;2-9, PubMed 9311595

Gaudernack G (1997)
Ras peptide vaccines
SYMPOSIUM IN IMMUNOLOGY VI: TUMOR IMMUNOLOGY, 137-146

Andersen SN, Løvig T, Breivik J, Lund E, Gaudernack G, Meling GI, Rognum TO (1997)
K-ras mutations and prognosis in large-bowel carcinomas
Scand J Gastroenterol, 32 (1), 62-9
DOI 10.3109/00365529709025065, PubMed 9018769

Gjersten MK, Saeterdal I, Beiske K, Gaudernack G (1996)
Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination
Cancer Immunol Immunother, 43 (5), 262-8
DOI 10.1007/s002620050332, PubMed 9024502

Donahue RE, Byrne ER, Thomas TE, Kirby MR, Agricola BA, Sellers SE, Gaudernack G, Karisson S, Lansdorp PM (1996)
Transplantation and gene transfer of the human glucocerebrosidase gene into immunoselected primate CD34+Thy-1+ cells
Blood, 88 (11), 4166-72
PubMed 8943851

Gjertsen MK, Saeterdal I, Thorsby E, Gaudernack G (1996)
Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination
Br J Cancer, 74 (11), 1828-33
DOI 10.1038/bjc.1996.638, PubMed 8956801

Steen R, Tjønnfjord GE, Gaudernack G, Brinch L, Egeland T (1996)
Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells
Br J Haematol, 94 (4), 597-605
DOI 10.1046/j.1365-2141.1996.7052322.x, PubMed 8826880

Norheim Andersen S, Breivik J, Løvig T, Meling GI, Gaudernack G, Clausen OP, Schjölberg A, Fausa O, Langmark F, Lund E, Rognum TO (1996)
K-ras mutations and HLA-DR expression in large bowel adenomas
Br J Cancer, 74 (1), 99-108
DOI 10.1038/bjc.1996.322, PubMed 8679466

Pettersen RD, Hestdal K, Lie SO, Gaudernack G (1996)
Role of the TCR binding region of the HLA class I alpha 2 domain in regulation of cell adhesion and proliferation
J Immunol, 156 (4), 1415-24
PubMed 8568242

Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde-Dahl T, Stokke KT, Sølheim BG, Egge TS, Søreide O, Thorsby E, Gaudernack G (1996)
Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study
Int J Cancer, 65 (4), 450-3
DOI 10.1002/(SICI)1097-0215(19960208)65:4<450::AID-IJC10>3.0.CO;2-E, PubMed 8621226

Gjertsen M, Bakka A, Soreide O, Thorsby E, Gaudernack G (1996)
Ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study
2ND WORLD CONGRESS - INTERNATIONAL HEPATO-PANCREATO-BILIARY ASSOCIATION, VOL II: BILIARY-PANCREAS, 1121-1125

Viken HD, Paulsen G, Drover S, Marshall WH, Sollid LM, Gaudernack G, Thorsby E (1995)
Influence on antibody recognition of amino acid substitutions in the cleft of HLA-DQ2 molecules. Suggestive evidence of peptide-dependent epitopes
Hum Immunol, 44 (2), 63-9
DOI 10.1016/0198-8859(95)00047-8, PubMed 8847230

Puri KD, Finger EB, Gaudernack G, Springer TA (1995)
Sialomucin CD34 is the major L-selectin ligand in human tonsil high endothelial venules
J Cell Biol, 131 (1), 261-70
DOI 10.1083/jcb.131.1.261, PubMed 7559783

Viken HD, Thorsby E, Gaudernack G (1995)
Characterization and epitope mapping of four HLA class II reactive mouse monoclonal antibodies using transfected L cells and human cells transfected with mutants of DQB1*0302
Tissue Antigens, 45 (4), 250-7
DOI 10.1111/j.1399-0039.1995.tb02448.x, PubMed 7638861

Olsen AC, Fossum B, Kirkin AF, Zeuthen J, Gaudernack G (1995)
A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses
Scand J Immunol, 41 (4), 357-64
DOI 10.1111/j.1365-3083.1995.tb03579.x, PubMed 7899823

Viken HD, Paulsen G, Sollid LM, Lundin KE, Tjønnfjord GE, Thorsby E, Gaudernack G (1995)
Characterization of an HLA-DQ2-specific monoclonal antibody. Influence of amino acid substitutions in DQ beta 1*0202
Hum Immunol, 42 (4), 319-27
DOI 10.1016/0198-8859(94)00110-c, PubMed 7558917

Fossum B, Olsen AC, Thorsby E, Gaudernack G (1995)
CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13-->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation
Cancer Immunol Immunother, 40 (3), 165-72
DOI 10.1007/BF01517348, PubMed 7728775

Pettersen RD, Hestdal K, Lee N, Geraghty DE, Valø ET, Lie SO, Gaudernack G (1995)
RG1, a new murine monoclonal antibody recognizing a "supertypic" determinant on HLA-A molecules
Tissue Antigens, 45 (3), 203-12
DOI 10.1111/j.1399-0039.1995.tb02440.x, PubMed 7539160

Fossum B, Breivik J, Meling GI, Gedde-Dahl T, Hansen T, Knutsen I, Rognum TO, Thorsby E, Gaudernack G (1994)
A K-ras 13Gly-->Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation?
Int J Cancer, 58 (4), 506-11
DOI 10.1002/ijc.2910580409, PubMed 7914513

Johansen BH, Gedde-Dahl T, Sollid LM, Vartdal F, Thorsby E, Gaudernack G (1994)
Binding of ras oncogene peptides to purified HLA-DQ(alpha 1*0102,beta 1*0602) and -DR(alpha,beta 1*0101) molecules
Scand J Immunol, 39 (6), 607-12
DOI 10.1111/j.1365-3083.1994.tb03420.x, PubMed 8009176

Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G (1994)
K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location
Br J Cancer, 69 (2), 367-71
DOI 10.1038/bjc.1994.67, PubMed 8297737

Gedde-Dahl T, Spurkland A, Fossum B, Wittinghofer A, Thorsby E, Gaudernack G (1994)
T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA
Eur J Immunol, 24 (2), 410-4
DOI 10.1002/eji.1830240221, PubMed 7507844

Gedde-Dahl T, Nilsen E, Thorsby E, Gaudernack G (1994)
Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras
Cancer Immunol Immunother, 38 (2), 127-34
DOI 10.1007/BF01526208, PubMed 8306368

Ghaderi AA, Gaudernack G, Stanworth DR (1994)
Cross-linking of a sequential epitope within the beta-chain of HLA-DR/DP molecules suppressing B lymphocyte growth and inducing homotypic cell aggregation
Immunol Lett, 39 (2), 113-9
DOI 10.1016/0165-2478(94)90095-7, PubMed 7516911

Fossum B, Gedde-Dahl T, Breivik J, Eriksen JA, Spurkland A, Thorsby E, Gaudernack G (1994)
p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp)
Int J Cancer, 56 (1), 40-5
DOI 10.1002/ijc.2910560108, PubMed 7903287

Spurkland A, Gedde-Dahl T, Hansen T, Vartdal F, Gaudernack G, Thorsby E (1994)
Heterogeneity of T cells specific for a particular peptide/HLA-DQ complex
Hum Immunol, 39 (1), 61-8
DOI 10.1016/0198-8859(94)90102-3, PubMed 8181964

EGELAND T, GAUDERNACK G (1994)
IMMUNOMAGNETIC ISOLATION OF CD34+ CELLS - METHODOLOGY AND MONOCLONAL ANTIBODIES
HEMATOPOIETIC STEM CELLS: THE MULHOUSE MANUAL, 141-148

Fossum B, Gedde-Dahl T, Hansen T, Eriksen JA, Thorsby E, Gaudernack G (1993)
Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells
Eur J Immunol, 23 (10), 2687-91
DOI 10.1002/eji.1830231045, PubMed 7691613

Gedde-Dahl T, Fossum B, Eriksen JA, Thorsby E, Gaudernack G (1993)
T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction
Eur J Immunol, 23 (3), 754-60
DOI 10.1002/eji.1830230328, PubMed 8449222

Gedde-Dahl T, Olsen BH, Thorsby E, Gaudernack G (1993)
Oncogene-derived peptides: a new class of tumor rejection antigens?
Transplant Proc, 25 (1 Pt 2), 1385-6
PubMed 8442151

Egeland T, Tjønnfjord G, Steen R, Gaudernack G, Thorsby E (1993)
Positive selection of bone marrow-derived CD34 positive cells for possible stem cell transplantation
Transplant Proc, 25 (1 Pt 2), 1261-3
PubMed 7680152

Gedde-Dahl T, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G (1992)
Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61)
Int Immunol, 4 (11), 1331-7
DOI 10.1093/intimm/4.11.1331, PubMed 1282032

Brinchmann JE, Gaudernack G, Thorsby E, Vartdal F (1992)
Staphylococcal exotoxin superantigens induce human immunodeficiency virus type 1 expression in naturally infected CD4+ T cells
J Virol, 66 (10), 5924-8
DOI 10.1128/JVI.66.10.5924-5928.1992, PubMed 1356159

Smeland EB, Funderud S, Kvalheim G, Gaudernack G, Rasmussen AM, Rusten L, Wang MY, Tindle RW, Blomhoff HK, Egeland T (1992)
Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells
Leukemia, 6 (8), 845-52
PubMed 1379314

Pettersen KS, Wiiger MT, Narahara N, Andoh K, Gaudernack G, Prydz H (1992)
Induction of tissue factor synthesis in human umbilical vein endothelial cells involves protein kinase C
Thromb Haemost, 67 (4), 473-7
PubMed 1631796

Gedde-Dahl T, Eriksen JA, Thorsby E, Gaudernack G (1992)
T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides
Hum Immunol, 33 (4), 266-74
DOI 10.1016/0198-8859(92)90334-j, PubMed 1639630

Onsrud M, Grahm I, Gaudernack G, Tropé C (1992)
Lymphoid cell distribution as prognostic factor in carcinoma of the uterine cervix
Acta Obstet Gynecol Scand, 71 (2), 135-9
DOI 10.3109/00016349209007971, PubMed 1316042

EGELAND T, QUARSTEN H, GAUDERNACK G (1992)
EFFECT OF RECOMBINANT STEM-CELL GROWTH-FACTORS ON IMMUNOMAGNETICALLY ISOLATED CD34+ CELLS
INT J CELL CLONING, 10 1, 53-55
DOI 10.1002/stem.5530100719

Egeland T, Steen R, Quarsten H, Gaudernack G, Yang YC, Thorsby E (1991)
Myeloid differentiation of purified CD34+ cells after stimulation with recombinant human granulocyte-monocyte colony-stimulating factor (CSF), granulocyte-CSF, monocyte-CSF, and interleukin-3
Blood, 78 (12), 3192-9
PubMed 1720697

Gjertsen HA, Lundin KE, Rønningen KS, Gaudernack G, Thorsby E (1991)
T cells recognizing an HLA-DQ alpha beta heterodimer encoded in cis by the DR4DQw4 haplotype and in trans by DR4DQw8/DRw8DQw4 heterozygous cells
Hum Immunol, 30 (3), 226-32
DOI 10.1016/0198-8859(91)90039-c, PubMed 2055788

Brinchmann JE, Gaudernack G, Vartdal F (1991)
In vitro replication of HIV-1 in naturally infected CD4+ T cells is inhibited by rIFN alpha 2 and by a soluble factor secreted by activated CD8+ T cells, but not by rIFN beta, rIFN gamma, or recombinant tumor necrosis factor-alpha
J Acquir Immune Defic Syndr (1988), 4 (5), 480-8
PubMed 1673156

Brun A, Gaudernack G, Sandberg S (1990)
A new method for isolation of reticulocytes: positive selection of human reticulocytes by immunomagnetic separation
Blood, 76 (11), 2397-403
PubMed 2257309

Müller F, Rollag H, Gaudernack G, Frøland SS (1990)
Impaired in vitro survival of monocytes from patients with HIV infection
Clin Exp Immunol, 81 (1), 25-30
DOI 10.1111/j.1365-2249.1990.tb05286.x, PubMed 1974179

Skjønsberg C, Kiil Blomhoff H, Gaudernack G, Funderud S, Beiske K, Smeland EB (1990)
Immunological typing of acute leukaemias by rosetting with immunomagnetic beads: comparison with immunofluorescence staining
Scand J Immunol, 31 (5), 567-73
DOI 10.1111/j.1365-3083.1990.tb02807.x, PubMed 2189214

Brinchmann JE, Gaudernack G, Vartdal F (1990)
CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor
J Immunol, 144 (8), 2961-6
PubMed 1969879

Lundin KE, Sollid LM, Bosnes V, Gaudernack G, Thorsby E (1990)
T-cell recognition of HLA class II molecules induced by gamma-interferon on a colonic adenocarcinoma cell line (HT29)
Scand J Immunol, 31 (4), 469-75
DOI 10.1111/j.1365-3083.1990.tb02794.x, PubMed 2110380

Molloy A, Gaudernack G, Levis WR, Cohn ZA, Kaplan G (1990)
Suppression of T-cell proliferation by Mycobacterium leprae and its products: the role of lipopolysaccharide
Proc Natl Acad Sci U S A, 87 (3), 973-7
DOI 10.1073/pnas.87.3.973, PubMed 1689064

Hovdenes J, Gaudernack G, Kvien TK, Hovdenes AB, Egeland T (1989)
Mitogen-induced interleukin 2 and gamma interferon production by CD4+ and CD8+ cells of patients with inflammatory arthritides. A comparison between cells from synovial fluid and peripheral blood
Scand J Immunol, 30 (5), 597-603
DOI 10.1111/j.1365-3083.1989.tb02467.x, PubMed 2511620

Solum NO, Aakhus AM, Pedersen T, Gaudernack G (1989)
The PhastSystem equipment used for crossed immunoelectrophoresis combined with immunoblotting of coprecipitated monoclonal antibodies as studied with platelet membrane receptor proteins
Electrophoresis, 10 (11), 752-8
DOI 10.1002/elps.1150101104, PubMed 2612475

Lundin KE, Rønningen KS, Aono S, Spurkland A, Gaudernack G, Isshiki G, Thorsby E (1989)
HLA-DQ antigens and DQ beta amino acid 57 of Japanese patients with insulin-dependent diabetes mellitus: detection of a DRw8DQw8 haplotype
Tissue Antigens, 34 (4), 233-41
DOI 10.1111/j.1399-0039.1989.tb02098.x, PubMed 2617513

Viken HD, Gaudernack G, Thorsby E (1989)
Characterization of a monoclonal antibody recognizing a polymorphic epitope mainly on HLA-DPw2 and DPw4 molecules
Tissue Antigens, 34 (4), 250-9
DOI 10.1111/j.1399-0039.1989.tb02100.x, PubMed 2482551

Brinchmann JE, Gaudernack G, Thorsby E, Jonassen TO, Vartdal F (1989)
Reliable isolation of human immunodeficiency virus from cultures of naturally infected CD4+ T cells
J Virol Methods, 25 (3), 293-300
DOI 10.1016/0166-0934(89)90056-6, PubMed 2573612

Lundin KE, Bosnes V, Gaudernack G (1989)
Human T lymphocyte clones: influence of culture conditions and optimization of proliferative assays
Scand J Immunol, 30 (1), 83-9
DOI 10.1111/j.1365-3083.1989.tb01191.x, PubMed 2787928

Holte H, Blomhoff HK, Beiske K, Funderud S, Torjesen P, Gaudernack G, Stokke T, Smeland EB (1989)
Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens
Eur J Immunol, 19 (7), 1221-5
DOI 10.1002/eji.1830190711, PubMed 2547623

CARLSEN E, GAUDERNACK G, FILIONMYKLEBUST C, PETTERSEN KS, PRYDZ H (1989)
ALLOGENEIC INDUCTION OF THROMBOPLASTIN SYNTHESIS IN MONOCYTES AND ENDOTHELIAL-CELLS - BIPHASIC EFFECT OF CYCLOSPORINE-A
Clin. Exp. Immunol., 76 (3), 428-433

Bosnes V, Halvorsen R, Skaftadottir I, Gaudernack G, Thorsby E (1989)
Specificity of gamma delta receptor-bearing cytotoxic T lymphocytes isolated from human peripheral blood
Scand J Immunol, 29 (6), 723-31
DOI 10.1111/j.1365-3083.1989.tb01177.x, PubMed 2525809

Hovdenes J, Gaudernack G, Kvien TK, Egeland T, Mellbye OJ (1989)
A functional study of purified CD4+ and CD8+ cells isolated from synovial fluid of patients with rheumatoid arthritis and other arthritides
Scand J Immunol, 29 (6), 641-9
DOI 10.1111/j.1365-3083.1989.tb01168.x, PubMed 2500703

Carlsen E, Gaudernack G, Filion-Myklebust C, Pettersen KS, Prydz H (1989)
Allogenic induction of thromboplastin synthesis in monocytes and endothelial cells. Biphasic effect of cyclosporin A
Clin Exp Immunol, 76 (3), 428-33
PubMed 2526700

Hovdenes J, Gaudernack G, Kvien TK, Egeland T (1989)
Expression of activation markers on CD4+ and CD8+ cells from synovial fluid, synovial tissue, and peripheral blood of patients with inflammatory arthritides
Scand J Immunol, 29 (6), 631-9
DOI 10.1111/j.1365-3083.1989.tb01167.x, PubMed 2544985

Leivestad T, Halvorsen R, Gaudernack G, Thorsby E (1989)
Ability of pure resting CD8+ human T cells to respond to alloantigen
Scand J Immunol, 29 (5), 543-53
DOI 10.1111/j.1365-3083.1989.tb01157.x, PubMed 2524873

Gaudernack G, Lundin KE (1989)
Rapid immunomagnetic phenotyping of cells
J Immunogenet, 16 (2), 169-75
DOI 10.1111/j.1744-313x.1989.tb00459.x, PubMed 2687387

Lundin KE, Ovigstad E, Sollid LM, Gjertsen HA, Gaudernack G, Thorsby E (1989)
Positive selection of Tac- (CD25) positive cells following T-cell activation. Use of immunomagnetic separation and implications for T-cell cloning
J Immunogenet, 16 (2), 185-91
DOI 10.1111/j.1744-313x.1989.tb00461.x, PubMed 2687389

Bosnes V, Halvorsen R, Gaudernack G, Thorsby E (1989)
Isolation of functionally active T cell receptor gamma delta-bearing lymphocytes from human peripheral blood
J Immunol Methods, 118 (2), 251-5
DOI 10.1016/0022-1759(89)90013-6, PubMed 2466905

Pfeffer PF, Gjertsen HA, Gaudernack G, Lexow PB, Sodal G, Thorsby E (1989)
Analysis of infiltrating lymphocytes from fine needle aspiration biopsies in kidney transplant patients by a rapid and sensitive immunomagnetic method
Transplant Proc, 21 (1 Pt 1), 354-5
PubMed 2495609

Leivestad T, Gaudernack G, Halvorsen R, Thorsby E (1988)
A simple and sensitive bioassay for the detection of IL-2 activity
J Immunol Methods, 114 (1-2), 95-9
DOI 10.1016/0022-1759(88)90159-7, PubMed 2972783

Kvalheim G, Funderud S, Kvaløy S, Gaudernack G, Beiske K, Jakobsen E, Jacobsen AB, Pihl A, Fodstad O (1988)
Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation
J Natl Cancer Inst, 80 (16), 1322-5
DOI 10.1093/jnci/80.16.1322, PubMed 3050139

Halvorsen R, Leivestad T, Gaudernack G, Thorsby E (1988)
Induction of interleukin-2 production in CD4+ and CD8+ T-cell subsets after activation via CD3 and CD2
Scand J Immunol, 28 (4), 449-55
DOI 10.1111/j.1365-3083.1988.tb01475.x, PubMed 2904172

Halvorsen R, Leivestad T, Gaudernack G, Thorsby E (1988)
Accessory cell-dependent T-cell activation via Ti-CD3. Involvement of CD2-LFA-3 interactions
Scand J Immunol, 28 (3), 277-84
DOI 10.1111/j.1365-3083.1988.tb01449.x, PubMed 2461580

Lundin KE, Gaudernack G, Qvigstad E, Sollid LM, Thorsby E (1988)
T lymphocyte clones recognizing an HLA-DQw3.2-associated epitope involving residue 57 on the DQ beta chain
Hum Immunol, 22 (4), 235-46
DOI 10.1016/0198-8859(88)90003-1, PubMed 2459088

Leivestad T, Halvorsen R, Gaudernack G, Thorsby E (1988)
Requirements for phytohaemagglutinin activation of resting pure CD4+ and CD8+ T cells
Scand J Immunol, 27 (5), 565-72
DOI 10.1111/j.1365-3083.1988.tb02384.x, PubMed 3131868

Halvorsen R, Leivestad T, Gaudernack G, Thorsby E (1988)
Role of accessory cells in the activation of pure T cells via the T cell receptor-CD3 complex or with phytohaemagglutinin
Scand J Immunol, 27 (5), 555-63
DOI 10.1111/j.1365-3083.1988.tb02383.x, PubMed 2967540

Helgestad J, Bøyum A, Storm-Mathisen I, Gaudernack G, Lie SO (1988)
Human granulopoiesis in vitro--medium-dependent growth regulation by a granulocyte-derived inhibitor
Acta Physiol Scand, 133 (1), 41-7
DOI 10.1111/j.1748-1716.1988.tb08379.x, PubMed 3265841

Markussen G, Rønningen KS, Paulsen G, Gaudernack G, Sollid LM, Thorsby E (1988)
HLA-DQw3.1 and DQw3.2 associated exon polymorphisms detected by oligonucleotide probes
Tissue Antigens, 31 (4), 204-10
DOI 10.1111/j.1399-0039.1988.tb02082.x, PubMed 3406934

Thorsen LI, Gaudernack G, Hack N, Wilkinson JM, Brosstad F, Solum NO, Crawford N (1988)
Characterization of a monoclonal antibody ITI-Pl 1 directed against human platelet membrane glycoprotein IIb using extracts of whole platelets and platelet surface and intracellular membranes
Br J Haematol, 68 (1), 67-74
DOI 10.1111/j.1365-2141.1988.tb04181.x, PubMed 3278733

Lie O, Vartdal F, Funderud S, Gaudernack G, Olsaker I, Frøysadal E, Ugelstad J, Thorsby E (1988)
Immunomagnetic isolation of cells for serological BoLA typing
Anim Genet, 19 (2), 75-86
DOI 10.1111/j.1365-2052.1988.tb00794.x, PubMed 3137848

Tanum G, Gaudernack G (1988)
Small megakaryocytes--an identification problem
Res Exp Med (Berl), 188 (2), 95-9
DOI 10.1007/BF01852265, PubMed 2453905

Brinchmann JE, Vartdal F, Gaudernack G, Markussen G, Funderud S, Ugelstad J, Thorsby E (1988)
Direct immunomagnetic quantification of lymphocyte subsets in blood
Clin Exp Immunol, 71 (1), 182-6
PubMed 3349645

Sollid LM, Brandtzaeg P, Kvale D, Gaudernack G, Scott H, Thorsby E (1988)
T cell-epithelium interactions in relation to gut immunity
Monogr Allergy, 24, 60-5
PubMed 3129651

Johne B, Bryn K, Gaudernack G, Myhrvold V, Morland B (1988)
Activation of mononuclear phagocyte functions by structurally different bacterial endotoxins
Adv Exp Med Biol, 237, 783-7
DOI 10.1007/978-1-4684-5535-9_117, PubMed 3075875

Johne B, Gaudernack G, Mørland B (1987)
Effects of endotoxins from Bacteroides intermedius and Escherichia coli on human monocytes in vitro
Acta Pathol Microbiol Immunol Scand C, 95 (6), 241-50
DOI 10.1111/j.1699-0463.1987.tb00037.x, PubMed 2964769

Halvorsen R, Gaudernack G, Leivestad T, Vartdal F, Thorsby E (1987)
Activation of resting, pure CD4+, and CD8+ cells via CD3. Requirements for second signals
Scand J Immunol, 26 (2), 197-205
DOI 10.1111/j.1365-3083.1987.tb02252.x, PubMed 2957786

Thorsen LI, Gaudernack G, Brosstad F, Pedersen TM, Solum NO (1987)
Identification of platelet antigens by monoclonal antibodies using crossed immunoelectrophoresis with immunoblotting of the monoclonal antibody
Thromb Haemost, 57 (2), 212-6
PubMed 3299855

Mørk NJ, Gaudernack G, Braathen LR (1987)
Effect of UVA and PUVA on alloactivating and antigen-presenting capacity of human epidermal Langerhans cells
Photodermatol, 4 (2), 66-72
PubMed 3498937

Vartdal F, Kvalheim G, Lea TE, Bosnes V, Gaudernack G, Ugelstad J, Albrechtsen D (1987)
Depletion of T lymphocytes from human bone marrow. Use of magnetic monosized polymer microspheres coated with T-lymphocyte-specific monoclonal antibodies
Transplantation, 43 (3), 366-71
DOI 10.1097/00007890-198703000-00010, PubMed 3103274

Leivestad T, Gaudernack G, Ugelstad J, Vartdal F, Thorsby E (1987)
Isolation of pure and functionally active T4 and T8 cells by positive selection with antibody-coated monosized magnetic microspheres
Transplant Proc, 19 (1 Pt 1), 265-7
PubMed 3152700

Sollid LM, Gaudernack G, Markussen G, Kvale D, Brandtzaeg P, Thorsby E (1987)
Induction of various HLA class II molecules in a human colonic adenocarcinoma cell line
Scand J Immunol, 25 (2), 175-80
DOI 10.1111/j.1365-3083.1987.tb01061.x, PubMed 2434988

Vartdal F, Bratlie A, Gaudernack G, Funderud S, Lea T, Thorsby E (1987)
Microcytotoxic HLA typing of cells directly isolated from blood by means of antibody-coated microspheres
Transplant Proc, 19 (1 Pt 1), 655-7
PubMed 3152705

Sollid L, Paulsen G, Gaudernack G, Thorsby E (1987)
HLA class II profile of a human carcinoma cell line: detection on genomic level and after exposure to gamma-interferon
Transplant Proc, 19 (1 Pt 1), 215
PubMed 3152692

VARTDAL F, ALBRECHTSEN D, RINGDEN O, KVALHEIM G, LEA T, BOSNES V, GAUDERNACK G, BRINCHMANN J, UGELSTAD J (1987)
IMMUNOMAGNETIC TREATMENT OF BONE-MARROW ALLOGRAFTS
Bone Marrow Transplant., 2 2, 94-98

Vartdal F, Gaudernack G, Funderud S, Bratlie A, Lea T, Ugelstad J, Thorsby E (1986)
HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation--a fast and reliable technique
Tissue Antigens, 28 (5), 301-12
DOI 10.1111/j.1399-0039.1986.tb00500.x, PubMed 3469787

LEIVESTAD T, GAUDERNACK G, QVIGSTAD E, UGELSTAD J, THORSBY E (1986)
ISOLATION OF FUNCTIONALLY ACTIVE T-CELL SUBSETS BY MONOCLONAL-ANTIBODIES CONJUGATED TO MONODISPERSE MAGNETIC MICROSPHERES (M-450)
Transplant. Proc., 18 (4), 731-732

Leivestad T, Gaudernack G, Ugelstad J, Thorsby E (1986)
Positive selection of activated T cells of the T8 (CD8) sub-type by immunomagnetic separation
Tissue Antigens, 28 (1), 46-52
DOI 10.1111/j.1399-0039.1986.tb00459.x, PubMed 3018960

Gaudernack G, Leivestad T, Ugelstad J, Thorsby E (1986)
Isolation of pure functionally active CD8+ T cells. Positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres
J Immunol Methods, 90 (2), 179-87
DOI 10.1016/0022-1759(86)90074-8, PubMed 3088118

Sollid L, Bruserud O, Gaudernack G, Thorsby E (1986)
The role of the CD8-positive subset of T cells in proliferative responses to soluble antigens. I. Studies of healthy subjects, type 1 diabetics, and coeliac disease patients
Scand J Immunol, 23 (4), 461-7
DOI 10.1111/j.1365-3083.1986.tb03077.x, PubMed 3010443

Bruserud O, Sollid L, Gaudernack G, Thorsby E (1986)
The role of the CD8-positive subset of T cells in proliferative responses to soluble antigens. II. CD8-positive cells are not responsible for DR-associated differences in responsiveness to mumps and Coxsackie B4
Scand J Immunol, 23 (4), 469-73
PubMed 3010444

Bjercke S, Onsrud M, Gaudernack G (1986)
Suppressive effect of monocytes in vitro in patients with carcinoma of the uterine cervix
Acta Obstet Gynecol Scand, 65 (6), 619-24
DOI 10.3109/00016348609158399, PubMed 3026137

Onsrud M, Grahm I, Gaudernack G (1986)
Early stage carcinoma of the uterine cervix. Effects of intracavitary radium treatment on lymphoid cells in blood and pelvic lymph nodes
Acta Radiol Oncol, 25 (2), 127-30
DOI 10.3109/02841868609136390, PubMed 3012956

Hetland O, Brovold AB, Holme R, Gaudernack G, Prydz H (1985)
Thromboplastin (tissue factor) in plasma membranes of human monocytes
Biochem J, 228 (3), 735-43
DOI 10.1042/bj2280735, PubMed 4026807

Gaudernack G, Bjercke S (1985)
Dendritic cells and monocytes as accessory cells in T-cell responses in man. I. Phenotypic analysis of dendritic cells and monocytes
Scand J Immunol, 21 (5), 493-500
DOI 10.1111/j.1365-3083.1985.tb01838.x, PubMed 3923613

Bjercke S, Gaudernack G, Braathen LR (1985)
Enriched Langerhans cells express more HLA-DR determinants than blood-derived adherent cells (monocytes and dendritic cells)
Scand J Immunol, 21 (5), 489-92
DOI 10.1111/j.1365-3083.1985.tb01837.x, PubMed 2408326

Bjercke S, Gaudernack G (1985)
Dendritic cells and monocytes as accessory cells in T-cell responses in man. II. Function as antigen-presenting cells
Scand J Immunol, 21 (5), 501-8
DOI 10.1111/j.1365-3083.1985.tb01839.x, PubMed 3873688

GAUDERNACK G, BJERCKE S, THORSBY E (1985)
EXPRESSION OF HLA CLASS-II MOLECULES ON HUMAN-MONOCYTES AND DENDRITIC CELLS
Transplant. Proc., 17 (1), 961-962

Andersen OK, Osterud B, Gaudernack G, Lundgren TI, Giercksky KE (1985)
Tissue thromboplastin generation in circulating mononuclear phagocytes and development of coagulation disorders during E. coli endotoxinaemia in pigs
Acta Chir Scand, 151 (3), 205-11
PubMed 3925666

Bjercke S, Braathen L, Gaudernack G, Thorsby E (1985)
Relative efficiency of human Langerhans' cells and blood derived dendritic cells as antigen-presenting cells
Acta Derm Venereol, 65 (5), 374-8
PubMed 2416158

Qvigstad E, Gaudernack G, Thorsby E (1984)
Antigen-specific T cell clones restricted by DR, DRw53 (MT), or DP (SB) Class II HLA molecules. Inhibition studies with monoclonal HLA-specific antibodies
Hum Immunol, 11 (4), 207-17
DOI 10.1016/0198-8859(84)90060-0, PubMed 6210280

Gaudernack G, Halvorsen O, Skorping A, Stokkan KA (1984)
Humoral immunity and output of first-stage larvae of Elaphostrongylus rangiferi (Nematoda, Metastrongyloidea) by infected reindeer, Rangifer tarandus tarandus
J Helminthol, 58 (1), 13-8
DOI 10.1017/s0022149x0002798x, PubMed 6371122

Gaudernack G, Olstad R (1983)
Tumor--host interactions in vivo. II. Induction of NK-cell activity by intraperitoneal injection of murine sarcoma cells or tumor ascites fluid
Scand J Immunol, 17 (3), 275-82
DOI 10.1111/j.1365-3083.1983.tb00790.x, PubMed 6828825

Marhaug G, Gaudernack G, Bogen B, Husby G (1982)
Monoclonal hybridoma antibodies to human amyloid related protein SAA
Clin Exp Immunol, 50 (2), 390-6
PubMed 7151332

Kaplan G, Gaudernack G (1982)
In vitro differentiation of human monocytes. Differences in monocyte phenotypes induced by cultivation on glass or on collagen
J Exp Med, 156 (4), 1101-14
DOI 10.1084/jem.156.4.1101, PubMed 6961188

Vercelotti G, Mullins W, Curry R, Gaudernack G, Moldow C, Messner RP (1982)
A unique monoclonal antibody inhibits the second wave of platelet aggregation
Clin Immunol Immunopathol, 23 (3), 691-7
DOI 10.1016/0090-1229(82)90332-4, PubMed 6981480

Curry R, Thoen J, Shelborne C, Gaudernack G, Messner R (1982)
Antibodies to and elevations of beta 2 microglobulin in the serum of ankylosing spondylitis patients
Arthritis Rheum, 25 (4), 375-80
DOI 10.1002/art.1780250403, PubMed 6176246

Gaudernack G, Curry R, Messner R (1981)
Rapid identification of human B-lymphocytes and monocytes with rhodamine-labeled Brucella melitensis
J Immunol Methods, 43 (3), 251-9
DOI 10.1016/0022-1759(81)90172-1, PubMed 6972976

Olstad R, Gaudernack G, Kaplan G, Seljelid R (1980)
T- and B-cell-independent activation of syngeneic macrophages by murine sarcoma cells
Cancer Res, 40 (6), 2054-60
PubMed 6966185

OLSTAD R, GAUDERNACK G, KAPLAN G, SELJELID R (1980)
T-CELL AND B-CELL-INDEPENDENT ACTIVATION OF SYNGENEIC MACROPHAGES BY MURINE SARCOMA-CELLS
Cancer Res., 40 (6), 2054-2060

Jørgensen T, Gaudernack G, Hannestad K (1980)
Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315
Scand J Immunol, 11 (1), 29-35
DOI 10.1111/j.1365-3083.1980.tb00205.x, PubMed 9537026

Gaudernack G, Hannestad K (1979)
The plasma cell differentiation antigen PC.1 is absent in CH3/Tif and present in C3H/HeJ
Scand J Immunol, 9 (4), 373-9
DOI 10.1111/j.1365-3083.1979.tb03176.x, PubMed 87010

Jorgensen T, Gaudernack G, Hannestad K (1977)
Production of BALB/c anti-idiotypic antibodies against the BALB/c myeloma protein 315 does not require an intact ligand-binding site
Scand J Immunol, 6 (4), 311-8
DOI 10.1111/j.1365-3083.1977.tb00399.x, PubMed 67635

Hannestad K, Gaudernack G (1977)
Ligand-induced redistribution and augmentation of surface-bound myeloma protein on MOPC 315 plasmacytoma cells
Scand J Immunol, 6 (1-2), 59-76
DOI 10.1111/j.1365-3083.1977.tb00322.x, PubMed 403594

Gaudernack G, Prydz H (1975)
Studies on PIVKA-X
Thromb Diath Haemorrh, 34 (2), 455-64
PubMed 812196

Kaplan G, Gaudernack G, Seljelid R (1975)
Localization of receptors and early events of phagocytosis in the macrophage
Exp Cell Res, 95 (2), 365-75
DOI 10.1016/0014-4827(75)90562-5, PubMed 1193157

GAUDERNACK G, PRYDZ H (1975)
STUDIES ON PIVKA-X
THROMB DIATH HAEMOST, 34 (2), 455-464
DOI 10.1055/s-0038-1651404

Gaudernack G, Berre AG, Osterud B, Prydz H (1974)
Immunological studies on the blood coagulation Factor X and its warfarin-induced precursor
Thromb Diath Haemorrh, 31 (1), 40-51
PubMed 4209391

GAUDERNACK G, GLADHAUG.A, OSTERUD B, PRYDZ H (1974)
IMMUNOLOGICAL STUDIES ON BLOOD-COAGULATION FACTOR-X AND ITS WARFARIN-INDUCED PRECURSOR
THROMB DIATH HAEMOST, 31 (1), 40-51
DOI 10.1055/s-0038-1649144

Gaudernack G, Rugstad HE, Hegna I, Prydz H (1973)
Synthesis of serum proteins by a clonal strain of rat hepatoma cells
Exp Cell Res, 77 (1), 25-30
DOI 10.1016/0014-4827(73)90548-x, PubMed 4347806

Prydz H, Gaudernack G (1971)
Studies on the biosynthesis of factor VII (proconvertin). The mode of action of warfarin
Biochim Biophys Acta, 230 (2), 373-80
DOI 10.1016/0304-4165(71)90224-8, PubMed 4324764

Review articles

Ellingsen EB, Mangsbo SM, Hovig E, Gaudernack G (2021)
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential
Front Immunol, 12, 682492
DOI 10.3389/fimmu.2021.682492, PubMed 34290704

Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H (2014)
Therapeutic vaccines for cancer: an overview of clinical trials
Nat Rev Clin Oncol, 11 (9), 509-24
DOI 10.1038/nrclinonc.2014.111, PubMed 25001465

Breivik J, Gaudernack G (1999)
Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer
Adv Cancer Res, 76, 187-212
DOI 10.1016/s0065-230x(08)60777-0, PubMed 10218102

Gaudernack G (1996)
T cell responses against mutant ras: a basis for novel cancer vaccines
Immunotechnology, 2 (1), 3-9
DOI 10.1016/1380-2933(95)00028-3, PubMed 9373323